This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1363 entries already.
California-based biotech Electra Therapeutics Inc has secured US$183m in Series C financing. The investment comes from a consortium of four European investors and Mubadala Capital. Contrary to some reports, more SIRPα modulators exist than the investors initially indicated.
Pharma giant Ipsen will pay US$1bn to acquire French immuno-oncology firm ImCheck Therapeutics SAS. The deal includes US$350m upfront and up to US$650m in milestone payments. ImCheck focuses on butyrophilins, a new class of immune regulators, through its antibody programme ICT01, currently in Phase I trials.
Following its US$361 m Series C financing, Tubulis AG presented first Phase I/IIa data on its lead ADC, TUB-040, at ESMO 2025 in Berlin. The study focuseds on patients with platinum-resistant ovarian cancer (PROC). TUB-040 shows clear differentiation potential
Danish companies H. Lundbeck A/S (Lundbeck) and Contera Pharma A/S have inked a strategic research collaboration aiming at accelerating the development of oligonucleotide-based treatments for medically underserved neurological conditions.
The Merck subsidiary EMD Serono has agreed to price reductions of up to 84% for its in vitro fertilisation products in the United States. To avoid paying pharmaceutical tariffs, the company will distribute the products directly to self-paying patients via the TrumpRx.gov platform from 2026.
French ADC start-up Adcytherix SAS has added €105m Series A funding to a €30m seed financing round closed last year. With the money, the company will start a Phase I study with its lead ADCX-020 in Q1 2026 and develop novel payloads to break ADC therapy resistance.
Munich-Martinsried-based biotech Tubulis has closed a €308 million (USD 361 million) Series C financing round – the largest of its kind for a still existing European biotechnology company at the Series C stage and also the world’s largest financing for a private ADC (antibody–drug conjugate) developer. The attractivity lays in the technologyplatform of linking the payload.
Mainz Biomed NV may have taken a major step in early pancreatic cancer detection. The company reports that its multivariate RNA liquid biopsy test, licensed from Liquid Biosciences Inc. in March, achieved 100% sensitivity and 95% specificity in a feasibility study. The results suggest the test could detect cancer—and even precancerous lesions—earlier than current methods.
UK-based AstraZeneca plc has become the second of 17 pharmaceutical companies, after Pfizer Inc., to accept U.S. President Donald Trump’s proposal to voluntarily lower drug prices and move production to the United States. In return, the company will benefit from a three-year exemption from U.S. import tariffs on prescription drugs manufactured outside the country.
At BioSpain 2025 European Biotechnology spoke with AseBio CEO Ion Arocena about Spain’s expansion in biotech and its role in a time of geopolitical tensions.